Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data
Endocrine-Related Cancer · 01.08.2026 · 33 (8)
DOI: 10.1530/erc-25-0531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 14.07.2026. Verfasst von Steven G Waguespack und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Pyrazoles, Pyrimidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Larotrectinib is a first-in-class, highly selective, central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for tumour-agnostic use in TRK fusion cancer. It has previously demonstrated rapid and durable disease control and favourable safety in patients with advanced TRK fusion thyroid carcinoma (TC). After an additional 4 years of follow-up with the inclusion of two additional patients, and utilising an independent review committee (IRC) to assess overall response rate (ORR), we report updated pooled analyses from three phase 1–2 larotrectinib clinical trials, focusing only on patients with TRK fusion differentiated TC (DTC). The primary endpoint was the IRC-determined ORR per RECIST v1.1. Duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety were also assessed. Twenty-four patients (papillary TC, n = 21; follicular TC, n = 2; poorly DTC, n = 1) were included (data cut-off: 20 July 2024). ORR was 79% (95% confidence interval (CI): 58–93); best responses were complete response in 3 (13%) patients, partial response in 16 (67%), stable disease in 3 (13%), progressive disease in 1 (4%) and not evaluable in 1 (4%). Median DoR and PFS were 35 (95% CI: 22–not estimable (NE)) and 44 (95% CI: 35–NE) months, respectively; 6-year OS rate was 71% (95% CI: 50–91). Six patients remained on treatment. Treatment-related adverse events (TRAEs) were mainly grade 1/2; no patients permanently discontinued treatment due to TRAEs. Larotrectinib continues to demonstrate durable disease control, extended survival and a favourable long-term safety profile in patients with advanced TRK fusion DTC requiring systemic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA.
- Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University Hospital , Philadelphia, Pennsylvania, USA.
- Cancer Institute, Mass General Brigham Cancer Institute , Boston, Massachusetts, USA.
- Department of Oncology, St Vincent's University Hospital and Cancer Trials Ireland , Dublin, Ireland.
- Department of Medical Oncology, West Virginia University , Morgantown, West Virginia, USA.
- Department of Hematology/Oncology, Fox Chase Cancer Center , Philadelphia, Pennsylvania, USA.
ORCID-Profile: Steven G Waguespack, Marcia S Brose
Förderung
- NCI NIH HHS
Zitieren
APA
Waguespack, S. G., Brose, M. S., Lin, J. J., McDermott, R., Almubarak, M., Bauman, J., Casanova, M., Kummar, S., Lee, S. H., Rieke, D. T., Oh, D. Y., Qi, C., Neu, N., Burcoveanu, D. I., Mussi, C. E., Drilon, A., Hong, D. S., & Cabanillas, M. E. (2026). Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data. Endocrine-Related Cancer, 33(8). https://doi.org/10.1530/erc-25-0531
Vancouver
Waguespack SG, Brose MS, Lin JJ, McDermott R, Almubarak M, Bauman J, et al. Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data. Endocrine-Related Cancer. 2026;33(8). doi:10.1530/erc-25-0531
BibTeX
@article{Waguespack2026,
author = {Waguespack, Steven G and Brose, Marcia S and Lin, Jessica J and McDermott, Ray and Almubarak, Mohammed and Bauman, Jessica and Casanova, Michela and Kummar, Shivaani and Lee, Se-Hoon and Rieke, Damian T and Oh, Do-Youn and Qi, Changsong and Neu, Natascha and Burcoveanu, Domnita-Ileana and Mussi, Chiara E and Drilon, Alexander and Hong, David S and Cabanillas, Maria E},
title = {Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data},
journal = {Endocrine-Related Cancer},
year = {2026},
volume = {33},
number = {8},
doi = {10.1530/erc-25-0531}
}
EUVIMED